QLT, Inc. (NASDAQ: QLTI), a global biopharmaceutical company, has dedicated their efforts to discovering, developing and commercializing novel therapies. The company’s research and development efforts are focused on the field of ophthalmology. QLT leverages its three unique technology platforms, photodynamic therapy, Atrigel® and punctal plugs with drugs, to develop products such as Visudyne® and Eligard® and future product opportunities. For further information, visit the Company’s web site at www.qltinc.com.
- 17 years ago
QualityStocks
QLT, Inc. (NASDAQ: QLTI)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Narrows Q2 Loss 66% as E-Commerce Growth Offsets Healthcare Headwinds
NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company in healthcare and technology,…
-
QualityStocksNewsBreaks – Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Stands Distinct Against Walker Lane Backdrop
Lahontan Gold (TSX.V: LG) (OTCQB: LGCXF) is positioned as investors view the Walker Lane corridor in…
-
QualityStocksNewsBreaks – Solowin Holdings (NASDAQ: SWIN) Targets $1 Billion AUM for Tokenized USD Money Market Product by Year-End 2025
Solowin (NASDAQ: SWIN), a financial services firm bridging traditional and digital assets, announced an initiative…